Korea’s Celltrion, Partner Hospira Win Drug Procurement Bid In Norway For Infliximab Biosimilar
This article was originally published in PharmAsia News
Celltrion’s biosimilar infliximab has won over J&J’s Remicade in Norway’s national drug procurement bidding, and will be priced at a 39% discount to the originator product.
You may also be interested in...
The agency changes its rhetoric on the subject, inviting speculation about whether a marketing application has been received.
Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.
Phase III studies testing Dupixent in moderate-to-severe asthma were largely positive, but subgroup details raise questions about how it will compete against biologics targeting the IL-5 pathway. Some experts urge comparison trials to inform physicians' decisions about long-term use.